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Abstract: The picture of dynamic interaction between oncogenic viruses and the vaginal
bacteria-immune host milieu is incomplete. We evaluated the impact of Polyomaviridae, Papillomaviridae,
and Herpesviridae oncoviruses on the vaginal Community State Types (CSTs) and host immune
response in reproductive-age women. In our cohort, only Polyomaviridae and Papillomaviridae were
detected and were associated with changes in the resident bacteria of CST I and IV (p < 0.05).
Lactobacillus crispatus increased in CST I while Prevotella timonensis and Sneathia sanguinegens increased
in CST IV. Conversely, CST II and III showed an alteration of the immune response, with the decrease of
Eotaxin, MCP-1, IL-7, IL-9, and IL-15 (p < 0.05), leading to reduced antiviral efficacy. An efficient viral
clearance was observed only in women from CST I, dominated by Lactobacillus crispatus. Our in vivo
study begins to address the knowledge gap with respect to the role of vaginal bacteria and immune
response in susceptibility to oncoviral infections.
Keywords: virome; bacteriome; immune response; vagitypes
1. Introduction
The mutualism between the vaginal mucosa and its bacterial microbiome is a key point of
the physiologic condition of the female reproductive tract [1].
Cumulative pieces of evidence have shown that, alongside bacteria, viruses are a constitutive part
of the vaginal microbiome and that the virome is composed by both eukaryotic and prokaryotic viruses.
As the virome study methodologies improve, eukaryotic viruses causing latent or asymptomatic
infections are being recognized as the more prominent members of the vaginal microbiome, suggesting
an intimate relationship with both resident bacteria and host susceptibility and immune response to
viral infections [2].
Though to date, metagenomic studies on this complex interaction are far from reaching a complete
understanding, the most intriguing aspect is whether and how bacterial community may promote
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or inhibit viral pathogenesis [3]. A portion ranging from 15%–20% of all human cancers is caused
by oncogenic viruses [4]. The oncogenic viruses infecting the cervical tract can cause asymptomatic
latent infections and induce cellular transformation after many decades. Although each virus has its
own specific mechanism for promoting carcinogenesis, the ability of these viruses to establish a latent
persistent infection is critical to incidental viral tumorigenesis [5].
The vaginal dysbiosis of the mucosa-associated microbiota seems to represent a risk factor acting
as an enhancer of the tumorigenic potential through mechanisms including mucosal barrier failure
and inflammation [3]. These events increase the rate of a successful viral infection, enabling viral survival
in the cells through an asymptomatic and persistent nonlytic infection which determines a very subtle
inflammatory response and positively influences the induced tumorigenesis in immunosuppressed
women [2,6].
Since a persistent infection enables virus-induced tumorigenesis, we can develop new approaches
for preventing and treating malignancies by characterizing the host environment by which tumor
viruses achieve infection.
Wojciech Kwasniewski et al. hypothesized that a disturbed heterogeneity of the vaginal
microbiome is associated with Human Papilloma Virus (HPV)-induced carcinogenesis, identifying
the vaginal dysbiosis as a putative and potentially modifiable factor for HPV [7]. Moreover, a very
recent meta-analysis supported the hypothesis of a causal link between vaginal dysbiosis and cervical
cancer at several disease stages, affirming that a Lactobacillus dominating the vaginal microbiota might
reduce HPV-related disease burden or increase the viral clearance [8].
The “omics” technologies allowed us to discover that several divergent oncogenic viruses
promote tumorigenesis through shared host cell targets and pathways modulating the surrounding
microenvironment [9]. During the last few years, several observational studies reported oncogenic
viruses infecting the vaginal mucosa as a possible trigger for HPV in women of reproductive age,
including viral species belonging to the Polyomaviridae and Herpesviridae families. Despite this possible
finding, current knowledge on dynamic interaction with vaginal microbiome and host immune
response is scarce [10,11].
In this study, we integrated metagenomics and immune quantitative approaches to provide, to our
knowledge, the first in vivo view of the interaction of Papillomavirus, Polyomavirus, and Herpesvirus
oncogenic viruses with the vaginal community state types (CSTs) and local immune environments
before any clinical evidence of the cellular transformation is obtained.
2. Materials and Methods
2.1. Demographics of the Studied Cohort
During the first two months of 2018, 90 vaginal swabs from Caucasian immunocompetent women
of reproductive age (20–40) who visited the gynecological ambulatory of the IRCCS Burlo Garofolo,
Trieste, Italy, for urogenital complaints, were retrospectively selected on the basis of the following
exclusion criteria: pregnancy, menopause, 5–7 days after menstruation, antibiotic/probiotic therapy,
oral contraceptive use or hormonal replacement therapy, smoking, endocrine diseases, history of
cancer, current laboratory detection of STIs pathogens, HIV, and cervical-vaginal lesions.
After 8 months from the laboratory diagnosis, following the indications of the clinical protocol,
an additional vaginal swab was collected only from women who tested positive for viral infection
(n = 29).
Vaginal specimens were collected from each woman following a standard procedure using
a polyethylene Cervex brush device (Rovers Medical Devices B.V., Oss, The Netherlands). The swab
was suspended in 1.5 mL of TE buffer for microbiome assessment and immune factors dosage,
and stored at −80 ◦C.
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2.2. DNA Extraction and NGS Library Preparation
DNA was extracted from the swabs using the NucliSENS® easyMAG® system (BioMèrieux,
Gorman, North Carolina, CA, USA), following the manufacturer’s instructions, starting from 500 µL
of sample and with an elution volume of 50 µL. All DNA samples were stored at −80 ◦C prior to
further processing.
Firstly, a 500 base pair region of the V1-V3 portion of the 16S rRNA gene was amplified
and subsequently the 200 base pair region of the V3 portion was amplified as well, as described
elsewhere [12]. The V3 amplicon was used for template preparation by the Ion PGM Hi-Q View kit on
the Ion OneTouch™ 2 System (Life Technologies, Gran Island, New York, NY, USA) and sequenced
using the Ion PGM Hi-Q View sequencing kit (Life Technologies, New York, NY, USA) with the Ion
PGM™ System technology. Negative controls, including a no template control, were processed with
the clinical samples.
2.3. Big Data Processing
Quality filtering was performed using the software QIIME (Quantitative Insights Into Microbial
Ecology), version 1.9.1 [13]. Sequences with ambiguous bases and/or with mean Phred quality scores
≤20 were discarded. Taxonomic identities were assigned using the Vaginal 16S rRNA gene Reference
Database, which was constructed by Fettweis et al. [14], using open-reference OTU (Observational
Taxonomic Unit) picking with a uclust clustering tool. To reduce the risk of including OTUs that were
PCR artifacts, all OTUs that occurred in only one sample were removed. To control for differences in
sequencing depth between samples, we normalized the read counts by rarefying the otu table biom to
a depth of 5000 reads/sample.
2.4. Oncogenic Virome Analysis
The identification of infectious agents was performed using a highly sensitive species-specific
multiplex genotyping assay, combined with multiplex polymerase chain reaction (PCR),
and a bead-based Luminex technology (Luminex Corp., Austin, TX, USA). Multiplex type-specific
PCR (QIAGEN Multiplex PCR kit, Venlo, Netherlands) used primers specific to detect the presence
of 21 mucosal HPV types (HPV-6, -11, -16, -18, -26, -31, -33, -35, -39, -45, -51, -52, -53, -56, -58, -59,
-66, -68, -70, -73, and -82), 13 Polyomaviruses (BKPyV, JCPyV, KIPyV, MCPyV, WUPyV, TSPyV, HPyV6,
HPyV7, HPyV9, HPyV10, HPyV12, LIPyV, and SV40), and 10 Herpesviruses (CMV, EBV1, EBV2,
HSV1, HSV2, HHV3, HHV6A, HHV6B, HHHV7, and HHV8) [15,16], respectively. Two primer sets for
the amplification ofβ-globin were used as a positive control for the assessment of template DNA quality.
Briefly, the PCR products were generated, denatured, and hybridized to the bead-coupled probes in
96-well plates, as previously described [17,18]. Subsequently, the beads were analyzed in the Luminex
reader, the results were expressed as the median fluorescence intensity (MFI). The cut-off was computed
by adding 5 MFI to 1.1× the median background value.
2.5. Dosage of the Immune Soluble Factors
The concentrations of 48 cytokines, chemokines, and growth factors were analyzed by a quantitative
cytokine assay by means of the Bioplex Pro™human cytokine standard 27-plex and 21-plex panels based
on xMAP technology (Bio-Rad Laboratory, Hercules, CA, USA). Data were collected and analyzed
using a Bio-Rad BioPlex 200 instrument equipped with Bio-Plex Manager software version 6.0
(Bio-Rad Laboratory, Hercules, CA, USA). The immunoassay data were expressed in terms of mg
protein/mL estimated from Bradford protein concentration in respective samples using Bio-Rad
microtiter microassay kit (Bio-Rad Laboratory, Hercules, CA, USA) and human serum albumin
(Sigma Chemical, St. Louis, MO, USA), as recently published [12].
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2.6. Statistical Analysis
Using QIIME 1.9.1, Chao1, Observed OTUs, and Phylogenetic diversity (PD) whole tree metrics
were calculated to assess the alpha diversity and compared by means of a nonparametric T-test.
To highlight the differences in the microbial composition we applied a nonparametric T-test for
the pairwise comparisons.
To test the differences in the immune soluble factors, GraphPad Prism (v. 5, San Diego, CA USA)
was used. Specifically, the Kruskal-Wallis one-way analysis of variance was used for comparisons
between groups. When a significant p-value was observed (p < 0.05), a multiple comparison test was
used to determine which groups were different.
2.7. Data Availability
The dataset supporting the conclusions of this article has been uploaded to the National Center for
Biotechnology Information (NCBI) Sequence Read Archive (SRA) under the project number SRP152778.
3. Results
3.1. The Vaginal Bacteriome According to the Community State Types
Bacterial microbiome composition was evaluated in 90 vaginal swabs through sequencing of
the barcoded V3 region of the 16S rRNA gene, and the swabs were clustered into four community state
types (CSTs) based on the predominant Lactobacillus species. Four samples provided an exception since
the microbiome was characterized by a massive colonization of Bifidobacteria, classified as B group
for two of them, and the remaining two, classified as Mixed CST, showed two dominant Lactobacilli
at equal amounts (in one sample L. crispatus and L. gasseri and in two samples L. crispatus and L. iners).
We obtained a total of 5,683,658 reads (range 1278–190,380) and a total number of observed OTUs
of 11,168. For the analyses, we rarefied the otu_table.biom to a depth of 5000 reads/sample, excluding
four samples. The two negative controls did not produce an output after the quality filtering.
Figure 1 shows the identified microbiome, sub-grouped according to the presence (black cells)
or absence (white cells) of oncogenic viral strains.
Figure 2 highlights the mean relative abundance of the dominant bacteria of each CST
and the significantly varied bacteria among CSTs. In CST I, the mean relative abundance of
Lactobacillus crispatus was 72%, while in CST II, the average relative abundance of Lactobacillus
gasseri was 58%. In CST III, Lactobacillus iners was 94%, while in CST IV, G. vaginalis was 10%. L. iners
(40%) and B. breve (58%) were the dominant species in Mixed and B groups, respectively.
CST IV, as expected, showed the highest bacterial heterogeneity, including the colonization by
a high rate of Gram-positive microorganisms (26%) dominated by Streptococcus spp. (12%) and by
Gram-negative species such as Atopobium vaginae (7%) and Escherichia fergusonii (5%), compatible with
a status of dysbiosis and biofilm production. Conversely, the CST III was the most homogeneous
group, showing only the 6% of bacterial species that were different from L. iners (94%), underscoring its
ability to colonize the vaginal epithelium both in eubiotic and dysbiotic conditions. Indeed, the alpha
diversity showed a significant decrease only for samples from CST III (p < 0.005), showing the most
homogeneous bacterial composition. When viral infected CSTs were compared with the corresponding
negative ones, no statistical variation was observed (Table 1).
Ureaplasma parvum has been detected only in the CST I and CST II where, in this last group,
U. parvum showed the highest rate of colonization. Moreover, Gardnerella vaginalis has been detected in
all samples, but with a relative amount inversely proportional to that of Lactobacilli spp. (Figure 2).
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Figure 1. The microbiome composition according to the community state types (CSTs) classification.
The heat map shows the relative abundances of the bacteria identified in the CSTs groups: CST I is
dominated by L. crispatus, CST II by L. gasseri, CST III by L. iners, and CST IV is depleted of Lactobacilli.
The relative abundances were calculated on the rarefied_otu_table.biom (5000 reads/sample) by means
of the summarize_taxa.py script (QIIME 1.9.1). Within each CST, the black bars identify the viral
DNA positive samples. Abbreviations: M: mixed CST; B: Bifidobacteria.
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Figure 2. The bacterial differences among CSTs. The figure shows the significantly modulated bacteria
among CSTs (p value < 0.05). Differences were calculated by means of a non-parametric T-test
for pairwise comparisons among CSTs (Quantitative Insights Into Microbial Ecology, QIIME, 1.9.1).
White bars show significant comparisons. * p < 0.05; ** p < 0.01.
Table 1. Comparison of bacterial diversity among CSTs. Bacterial alpha diversity values are given
as the mean ± standard deviation at a rarefaction depth of 5000 sequences per sample. Alpha diversity
was compared among CSTs and, within each CST, between viral DNA positive and negative samples
by means of a non-parametric t-test using the compare_alpha_diversity.py script of QIIME. a= p < 0.05
for CST III vs CST I and for CST III vs CST IV.
CST I (18) CST II (13) CST III (28) CST IV (22) MixedCST (3)
Bifidobacteria
(2)
Chao1 300 ± 106 282 ± 123 181 ± 103 274 ± 108 252 ± 147 281 ± 131
Observed otus 114 ± 40 110 ± 43 70 ± 37a 125 ± 40 104 ± 54 99 ± 125
PD whole tree 10 ± 3 9 ± 3 7 ± 3 10 ± 3 9 ± 3 10 ± 2
Virus Virus Virus Virus Virus Virus
+ (7) - (11) + (3) - (10) + (12) - (16) + (6) - (16) + - + (1) - (1)
Chao1 294 ± 123 305 ± 94 177 ± 90 314 ± 113 190 ± 85 174 ± 116 252 ± 133 282 ± 95
Na
413 150
Observed otus 114 ± 45 114 ± 36 82 ± 37 66 ± 42 73 ± 29 66 ± 42 124 ± 59 125 ± 31 129 69
PD whole tree 10 ± 3 10 ± 3 7 ± 2 10 ± 3 8 ± 2 7 ± 3 9 ± 3 9 ± 3 12 8
3.2. Papillomavirus, Polyomavirus and Herpesvirus Oncogenic Virome According to CSTs
The virome analysis highlighted that a small cluster of oncogenic viruses, including Papillomaviridae
and Polyomaviridae family strains, were present in our series and they were not preferentially identified
in a given CST (Figure 3). We did not identify Herpesviridae family strains in our cohort. In 29/86 (33.7%)
samples, DNA of oncogenic viruses was identified. MCPyV was the Polyomavirus most frequently
detected, while the HPV genotypes identified mostly belongs to the High-Risk HPV genotypes.
The highest rate of infection of this series was measured in CST III (43%, 12/28) and in CST I (38%, 7/18)
than in CST IV (27%, 6/22) and CST II (23%, 3/13). HPV DNA was more frequently associated with
CST IV (5/6) followed by CST III (8/28) while regarding Polyomaviruses, the highest rate of infection
was recovered in CST III (3/3) and CST I (5/7).
The overall distribution highlighted the strong presence of Polyomaviruses, specifically of JCPyV
and MCPyV, as unique or co-infections in all CST groups. In detail, in CST I, 2/7 samples were infected
with HPV, 1/7 with HPV/JCPyV, 1/7 with JCPyV/MCPyV and 3/7 with MCPyV. Among CST II samples,
1/3 showed HPV/MCPyV and 2/3 MCPyV. Within the CST III, 6/12 were infected with HPV, 1/12 with
HPV/JCPyV, 1/12 with HPV/MCPyV, 2/12 with JCPyV and MCPyV. In CST IV, 3/6 samples were infected
with HPV, 1/6 with HPV/JCPyV, 1/6 HPV/MCPyV and 1/6 with MCPyV.
One of the two remaining samples showing a massive presence of Bifidobacteria indicated a positive
sign positive for MCPyV. No viral infections were detected in the samples defined as mixed CST.
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Figure 3. The CSTs distribution. The grouping of samples according to the vaginal community state
types (CSTs) and the distribution of viruses within each CST. Abbreviations: GT: genotype; n = number
of samples.
3.3. Oncogenic Viral Infections and CSTs: Bacterial and Immune Responses
The effect of the oncogenic viral infections on the vaginal microbial composition and/or immune
environment perturbations was analyzed for each CST group and described in Figure 4.
Figure 4. The impact of viruses on the CSTs. The figure shows the significantly modulated aspects
between viral DNA negative vs. positive samples within each CST (p value < 0.05). Mixed CST
and Bifidobacteria groups are missing as the first group did not show viral DNA while the latter had only
one sample positive for viral DNA. Microbial differences were calculated by means of a non-parametric
T-test for pairwise comparisons among CSTs using QIIME 1.9.1 while immunological differences were
calculated using GraphPad Prism v. 5. The grey cells highlight the significant comparisons.
Considering oncogenic viruses as a variable, we observed a significant modulation only for
dominant bacteria characterizing CST I and IV samples (p < 0.05). Specifically, L. crispatus increased in
infected samples from CST I, showing a high rate infection with Polyomavirus, while Prevotella timonensis
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and Sneathia sanguinegens increased in infected samples from CST IV, characterized by a high rate of
HPV infection.
As detailed in Table 2, the basal status of the immune soluble environment for each CST group
in absence or presence of viral infections has been characterized and compared. Among the tested
47 immune soluble factors, several cytokines involved in inflammatory and anti-tumoral activities
showed a significant decrease in positive samples for oncogenic viruses. Among samples from CST II
and CST III, a significantly decreased concentration of the cytokines IL-7, Eotaxin and MCP1 was
detected in CST II while, in CST III, a decreased concentration was detected for IL-15 and IL-9 (p < 0.05).
Conversely, infected samples from CST I and CST IV did not show a significant variation of the immune
basal pattern.
3.4. Infection Follow-Up
Samples from women who tested positive for oncogenic viruses were recovered after eight months
from laboratory diagnosis for additional gynecological and microbiological evaluations, as indicated
by clinical protocol. Clinical examinations showed no sign of cervical lesions.
Microbiological analysis showed no residual viral DNA in 15/29 (51.7%) of the samples. To note,
clearance of the virus was more frequently observed in CST I group dominated by L. crispatus
(5/7 samples). Conversely, persistent infections due to HPV and Polyomavirus-HPV co-infections were
confirmed in CST III (9/12) and CST IV (5/6) groups, which are considered to indicate a transitional
state into a dysbiotic and a dysbiotic-BV like composition, respectively.
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Table 2. The impact of viruses on the immunological differences among CSTs. The figure shows the significantly modulated immune soluble factors between viral
DNA negative vs positive samples within each CST (p value < 0.05). Mixed CST and Bifidobacteria groups are missing as the first group did not show viral DNA while
the latter had only one sample positive for viral DNA. Differences were calculated by means of a non-parametric T test for pairwise comparisons among CSTs
(GraphPad Prism v. 5). Value are given as mean (pg/mL) ± standard error of the mean (SEM). *p < 0.05, ** p < 0.01, empty cell= p value not significant. Bold = higher
value within each CST.
CST I CST II CST III CST IV
Cytokines Virus + Virus - p Virus + Virus - p Virus + Virus - p Virus + Virus - p
IL-1α 28 ± 10 77 ± 41 26 ± 23 88 ± 56 54 ± 13 144 ± 45 289 ± 158 188 ± 80
IL-1β 21 ± 12 18 ± 6 47 ± 46 11 ± 5 39 ± 22 121 ± 56 77 ± 45 309 ± 142
IL-1ra 2 × 105 ± 8 × 105 2.3 × 105 ± 7 × 105 3.4 × 105 ± 3 × 105 3.6 × 105 ± 6 × 104 2 × 105 ± 3 × 104 4 × 105 ± 9 × 104 5 × 105 ± 9.6 × 104 3.2 × 105 ± 4.5 × 104
IL-2 2 ± 1 2 ± 0.7 1.3 ± 0.9 4 ± 1 0.6 ± 0.3 2 ± 0.6 3 ± 1.6 3 ± 0.7
IL-2ra 91 ± 33 28 ± 4 36 ± 23 49 ± 26 35 ± 9 46 ± 11 33 ± 9 40 ± 9
IL-3 132 ± 21 93 ± 8 57 ± 9 87 ± 9 100 ± 16 99 ± 12 80 ± 12 93 ± 8
IL-4 0.8 ± 0.3 0.7 ± 0.1 0.3 ± 0.3 0.8 ± 0.2 0.5 ± 0.1 0.8 ± 0.1 0.6 ± 0.5 0.5 ± 0.1
IL-5 0 ± 0 0 ± 0 0 ± 0 0.1 ± 0.1 0 ± 0 0.1 ± 0.1 0.7 ± 0.5 0 ± 0
IL-6 2.6 ± 0.3 3.4 ± 1 2.6 ± 1.7 4 ± 0.9 3 ± 0.7 5 ± 1 2 ± 1 3.7 ± 1
IL-9 9 ± 1.5 8 ± 2 12 ± 7 10 ± 2 5 ± 0.6 15 ± 3 ** 15 ± 3.4 8 ± 1.6
IL-10 1.3 ± 0.2 1.3 ± 0.1 1 ± 0 2 ± 0.1 1.6 ± 0.3 1.4 ± 0.2 1.5 ± 0.3 1.9 ± 0.3
IL-12p40 357 ± 38 332 ± 23 130 ± 26 305 ± 25 305 ± 39 301 ± 31 232 ± 63 303 ± 22
IL-12p70 6 ± 2 5.7 ± 1 2.6 ± 1 6 ± 1.4 5.7 ± 1 14 ± 4 6 ± 2.5 6 ± 1
IL-13 1 ± 0 1 ± 0 1 ± 0 1.1 ± 0.1 1 ± 0.1 1 ± 0.1 1 ± 0.3 1.1 ± 0.1
IL-15 1.4 ± 0.6 1.3 ± 0.5 1.7 ± 0.7 2 ± 0.6 1 ± 0.5 2 ± 0.3 * 2.8 ± 1.1 1.6 ± 0.5
IL-16 81.6 ± 24.2 36.5 ± 3.9 244 ± 194 51.3 ± 19.9 36.9 ± 5.8 52.7 ± 10.2 40.8 ± 8.82 39.7 ± 3.2
IL-17 7 ± 2 8.3 ± 2.5 6 ± 3 9 ± 3 8 ± 2 9.4 ± 2.2 7.3 ± 1.6 6 ± 0.8
IL-18 24 ± 2.8 710 ± 568 66 ± 32 340 ± 196 125 ± 84 198 ± 83 393 ± 238 1E3 ± 506
IFN-α2 29 ± 6 28 ± 11 14 ± 3 20 ± 5 18 ± 3.8 20 ± 3 17 ± 3 18 ± 2
IFN-γ 34 ± 11 22 ± 4 14 ± 6 29 ± 5 18 ± 3.5 31 ± 5 32 ± 16 24 ± 4
LIF 19 ± 2 20 ± 3 10 ± 2 16 ± 1.6 19 ± 2 19 ± 2.3 21 ± 6 23 ± 2.4
MIF 1.3 × 103 ± 1 × 103 822 ± 665 6 × 103 ± 4 × 103 1.3 × 103 ± 902 1 × 103 ± 685 1.7 × 103 ± 1 × 103 3.4 × 103 ± 2 × 103 3 × 103± 888
SCF 27 ± 8 15 ± 3 26 ± 24 11 ± 2 18 ± 5 18 ± 5 8 ± 3.2 16 ± 2.5
TNF-α 13 ± 1.6 12 ± 1.3 8 ± 3 17 ± 2 13 ± 3.4 20 ± 3 17 ± 7 29 ± 6
TNF-β 14 ± 4 10 ± 0.4 7.3 ± 0.3 9.4 ± 0.3 13 ± 3 11 ± 2 10 ± 0.8 10 ± 0.5
TRAIL 26 ± 2.4 21 ± 4.3 37 ± 13 18 ± 2.1 19 ± 1.6 23 ± 3.3 40 ± 11 29 ± 6
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Table 2. Cont.
CST I CST II CST III CST IV
Chemokines Virus + Virus - p Virus + Virus - p Virus + Virus - p Virus + Virus - p
cTACK 101 ± 24 66 ± 10 37 ± 12 79 ± 15 70 ± 21 58 ± 15 62 ± 26 80 ± 10
Eotaxin 52 ± 9 83 ± 41 17 ± 2 101 ± 39 ** 83 ± 37 170 ± 65 54 ± 29 55 ± 13
GRO- α 182 ± 108 632 ± 280 347 ± 318 521 ± 244 911 ± 248 959 ± 275 190 ± 102 907 ± 226
IL-8 144 ± 59 148 ± 33 294 ± 203 171 ± 43 207 ± 50 519 ± 188 745 ± 502 454 ± 99
IP-10 9 × 103 ± 7 × 103 2.5 × 104 ± 2 × 104 1.4 × 10
3 ± 1.2 ×
103 1.3 × 10
3 ± 399 1 × 10
4 ± 5.7 ×
103 4.5 × 10
4 ± 3 × 104 324 ± 129 1.9 × 104 ± 1.3 × 104
MCP-1 5 ± 0.5 10 ± 3.4 2.3 ± 0.3 5.5 ± 05 * 8 ± 2 6.3 ± 1.2 4 ± 1 5.3 ± 0.4
MCP-3 9 ± 2 6 ± 0.4 5.7 ± 0.7 6.5 ± 1 6.3 ± 1 7 ± 1 7.2 ± 1.3 7.5 ± 0.7
MIG 453 ± 257 288 ± 133 111 ± 65 149 ± 42 268 ± 170 724 ± 367 90 ± 36 312 ± 115
MIP-1 α 1.1 ± 0.1 2 ± 0.5 1.3 ± 0.3 1.1 ± 0.1 1.5 ± 0.3 2.2 ± 0.6 2.2 ± 1 2.7 ± 0.5
MIP-1 β 7 ± 2.5 21 ± 9 40 ± 38 14 ± 8 8 ± 3 40 ± 13 25 ± 11 32 ± 9
RANTES 7.4 ± 2 8.3 ± 2.2 2.3 ± 0.3 26 ± 19 16 ± 9 7 ± 1.5 15 ± 6 28 ± 9
SDF-1 α 147 ± 42 110 ± 22 77 ± 12 99 ± 19 130 ± 30 108 ± 14 101 ± 25 117 ± 12
CST I CST II CST III CST IV
Growth
factors Virus + Virus - p Virus + Virus - p Virus + Virus - p Virus + Virus - p
FGF- β 23 ± 5 24 ± 4 10 ± 2 22 ± 4.5 21.6 ± 3.4 22 ± 5 15 ± 4.1 17 ± 1.4
G-CSF 271 ± 172 212 ± 99 409 ± 384 89 ± 33 162 ± 57 686 ± 331 105 ± 79 116 ± 41
GM-CSF 93 ± 9 110 ± 7.7 68 ± 21 96 ± 6.6 91 ± 9.5 100 ± 10 81 ± 10 77 ± 6
HGF 172 ± 111 223 ± 149 387 ± 189 100 ± 35 235 ± 68 813 ± 402 300 ± 99 252 ± 95
IL-7 1 ± 0.3 1.5 ± 0.7 0 ± 0 1.4 ± 0.3 * 0.6 ± 0.2 1.3 ± 0.5 0.8 ± 0.6 0.9 ± 0.3
M-CSF 29 ± 8.3 29 ± 4.5 8.3 ± 3.3 27 ± 4 41 ± 5.2 44 ± 6.6 34 ± 13 33 ± 4
PDGF- β 16 ± 3 35 ± 13 10 ± 4.6 30 ± 6.4 28 ± 6.2 27 ± 7.2 17 ± 4 19 ± 5
SCGF- β 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
VEGF 53 ± 24 47 ± 12 29 ± 16 47 ± 16 57 ± 12 131 ± 50 58 ± 26 81 ± 23
β-NGF 3 ± 0.7 2 ± 0.3 2 ± 1 2 ± 0.5 1.8 ± 0.5 2.3 ± 0.5 2.6 ± 0.9 2.6 ± 0.4
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4. Discussion
One of the most interesting aspects of the virome world is its interaction with resident bacteria,
probably influencing viral infectivity and thus the infection outcome. These events, playing a central
role in shaping innate and adaptive immune defenses, are exerted during the early phase of viral entry,
clinically corresponding to the asymptomatic phase of infection [19,20].
Despite increased attention has been focused on the complexity of vaginal microbiome and its role
in women’s health, the modality of interaction between oncogenic viruses and local microenvironment
is still incomplete.
A crucial point is the definition of the vaginal milieu that may influence the susceptibility
and clearance of oncogenic viruses in women with an immune competent system, even if recent data
suggest the vaginal dysbiosis as a risk factor for viral infections [8].
In order to optimize the complexity of the vaginal microbial profiles, the vaginal CSTs classification
based on the central role of Lactobacillus spp. in orchestrating the vaginal composition and immune
defense has been exploited in our study [1]. This study-approach has proved a valuable tool for a better
characterization of the vaginal microbiome, as well as for providing direction on the events governing
microbiome-virome and host immune response interactions.
We reinforced the concept that the species of Lactobacillus characterizing CSTs represent a key factor
in influencing the modality of vaginal defense against viral infection through their direct involvement
or by the modulation of the local immune response [12]. In the CST I, dominated by L. crispatus,
the increase of the relative abundance of this Lactobacillus, as the main controlling infection defense
mechanism, did not modify the basal immune profile. The antiviral activity of L. crispatus has been
very recently reported in mammalian cell lines to be preventing HSV entry to cells [21] and blocking
progression of HPV cervical lesions [22]. To corroborate these data, we demonstrated that 70% of
women with a CST I profile cleared HPV and MCPyV infections in follow-up samples. Thus, suggesting
a high potential activity of L. crispatus as a first-line defense against HPV and MCPyV which share
similar pathogenic mechanisms, even if MCPyV only very recently has been proposed as a sexually
transmitted microorganism [23].
In contrast, in CST II dominated by L. gasseri and in CST III by L. iners, a different type of
host response resulting in the modulation of immune profile leading to the simultaneous increase
of pro-inflammatory cytokines and the decrease of anti-inflammatory and anti-tumoral factors
has been observed. In the CST IV, depleted of Lactobacilli, the increase of Sneathia sanguinegens
and Prevotella timonensis was observed in infected samples. Our in vivo study suggests the low
antiviral efficacy of L. gasseri and L. iners, in contrast with recent in vitro data pointing to a protective
anti-tumoral effect exerted by all Lactobacilli species colonizing the cervical epithelium [24].
Previous studies have indicated the vaginal dysbiosis as a risk factor for HPV infection, although
they cannot exclude reverse causation of HPV in altering the vaginal microbiome. A higher level of
Sneathia spp. has been observed in HPV-positive women and associated with all stages of cervical
carcinogenesis [25]. More recently, Mitra et al. identified S. sanguinegens to be more prevalent in
women with high-grade dysplasia compared to women with a low-grade dysplasia [26] while other
authors found an association of Prevotella spp. with symptomatic HPV infection [27].
We speculate that the composition of the vaginal microbiome “per se” is not a risk factor for
the acquisition of viral infection but it seems to influence the viral clearance.
In our cohort, we detected an increase of the relative abundance of Prevotella timonensis
and Sneathia sanguinegens in women infected with HPV or Polyomavirus during the asymptomatic phase
of infection, event probably facilitated by a steady state level of pro-inflammatory status characterizing
the vaginal environment of these women. Thus, it seems that both HPV and Polyomaviruses may
promote their active colonization of the mucosal microenvironment through immune evasion strategies,
mainly directed towards down-regulating the pro-inflammatory response. Indeed, a decreased
concentration of the pro-inflammatory IL-15, IL-7, and the anti-inflammatory IL-9 was observed.
The down-regulation of these molecules, which are first-line immune components for fighting viruses,
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prevents basically the growth and the activity of monocytes and T cells and, most importantly,
inhibits their immunostimulatory and immunomodulatory effects [28–30]. Moreover, there is wide
evidence supporting that host immunological features and local HPV-induced immunosuppressive
environment constitute crucial points in establishing a persistent infection [31]. This feature fits
our in vivo data in showing a low rate of viral clearance in women with a CST III or CST IV
vaginal microbiome.
Newly, the detection of MCPyV in the vaginal mucosa, as unique strain or in samples co-infected
with HPV, reinforces a role for this oncogenic Polyomavirus as a sexually transmitted pathogen,
although no significant association between MCPyV and cervical cancer has been already demonstrated.
To note, HPV and MCPyV co-occurrence was detected mainly in samples with molecular signatures of
mucosal inflammation, thereby indicating a similarity in the pathogenic pathway.
As already disclosed by several studies, the total Lactobacilli load in the vagina is not an accurate
parameter for asserting health status. Based on this observation, the introduction of CSTs has led
to the comprehension that species of Lactobacilli differently exert a protective role in oncogenic viral
infections. In addition, we highlighted that the microbiome heterogeneity is not predictive for
HPV and Polyomavirus susceptibility, which, on the contrary, seems to benefit from the steady-state
immune-bacterial crosstalk for establishing persistent infections. A main limitation of our study must
be identified in the small study cohort. For this reason, we believe that further studies are needed to
give more insights into the cross-talk between vaginal bacteriome and oncogenic virome.
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